source
- Amgen ends partnership with TScan Therapeutics as Amylyx announces $350 million offeringAmgen announced it is terminating its collaboration with TScan Therapeutics, a Waltham, Massachusetts company focused on T‑cell therapies. The decision ends a partnership that had been aimed at de…
- CSL Vifor warns Tavneos exit from Europe will cut revenue by about 25%CSL Vifor’s parent company CSL Limited said the withdrawal of the drug Tavneos from the European market creates a significant headwind for sales. The company expects its revenue to fall by roughly…